Oral Session

Oral Session 2-7B PTCL/NK lymphoma: Treatment (1)

Sat. Oct 13, 2018 10:10 AM - 11:10 AM No.7 (Osaka International Convention Center, 10F 1001)

Chair: Motoko Yamaguchi (Mie University Graduate School of Medicine, Japan)

+Add all to schedule

[OS2-7B-1] Peripheral T-cell lymphoma: prognosis according to retrospective analysis from a single-center

Yutaka Shimazu, Yayoi Shimazu, Hiroshi Shiragami, Satoko Oka, Masaharu Nohgawa (Department of Hematology, Japanese Red Cross Wakayama Medical Center)

[OS2-7B-2] Central nervous system relapse in peripheral T-cell lymphoma, a single institute experience

Fumihiko Mouri, Yoshitaka Yamasaki, Shuki Oya, Satoshi Morishige, Maki Yamaguchi, Atsushi Nonami, Ritsuko Seki, Koichi Osaki, Koji Nagafuji (hematol., kurume Univ., fukuoka, Japan)

[OS2-7B-3] A retrospective analysis of mature natural killer cell neoplasms

Tomohiro Taya, Kohei Tada, Chika Yamada, Hirotaka Nakamura, Ryosuke Nomura, Takaya Mitsuyoshi, Noriko Sugino, Masaharu Tashima, Hitomi Kaneko, Kazuo Hatanaka, Chisato Mizutani, Kazunori Imada (Hematology, Osaka Red Cross Hospital, Osaka, Japan)

[OS2-7B-4] A phase II study of THP-COP in newly diagnosed advanced peripheral T-cell lymphoma: THP-3 study

Michinori Ogura^1,2, Ken Ohmachi³, Ritsuro Suzuki⁴, Yoshiko Atsuta⁵, Tatsuya Ito⁶, Kazuma Ohyashiki⁷, Shingo Yano⁸, Michihiro Hidaka⁹, Kiyoshi Ando³, Noriko Fukuhara¹⁰, Yoshihisa Morishita¹¹, Takayo Suzuki¹², Kunihiro Tsukasaki¹³, Naoki Kobayashi¹⁴, Norifumi Tsukamoto¹⁵, Yukiyasu Ozawa¹⁶, Kazuhito Yamamoto¹⁷, Tomomitsu Hotta¹⁸, Tomohiro Kinoshita¹⁷ (1.Hematology/Oncology, Kasugai Municipal Hospital, Kasugai, Japan, 2.Hematology/Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan, 3.Hematology/Oncology.,Tokai Univ.,Isehara,Japan, 4.HSCT Data Manage. & Biostat., Nagoya Univ., Nagoya, Japan, 5.Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Nagoya, Japan, 6.Div. Hematol. & Oncol., Anjyo Kosei Hospital, Anjo, Japan, 7.Hematol. Tokyo Med. Univ., Tokyo, Japan, 8.Clin. Oncol. and Hematol., Jikei Univ., Tokyo, Japan, 9.Hematol., NHO KMC, Kumamoto, Japan, 10.Dept. Hematol. Rheumatol., Tohoku Univ., Sendai, Japan, 11.Hematol & Oncol, Konan Kosei Hospital, Konan, Japan, 12.Hematol & Oncol., Shiga Medical Center for Adults, Moriyama, Japan, 13.Hematol., Nagasaki University, Nagasaki, Japan, 14.Hematol., Sapporo Hokuyu Hospital, Sapporo, Japan, 15.Hematol, Gunma Univ, Gunma, Japan, 16.Hematol., JRC Nagoya Daiichi Hosp., Nagoya, Japan, 17.Dept Hematol Cell Therapy, Aichi Cancer Ctr, Nagoya, Japan, 18.National Cancer Center, Tokyo, Japan)

[OS2-7B-5] Phase III trial of mogamulizumab vs. vorinostat in previously treated cutaneous T-cell lymphoma

Kensei Tobinai¹, Makoto Sugaya², Noriko Fukuhara³, Yoshiki Tokura⁴ (1.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 2.Dermatology, International University of Health and Welfare, Ichikawa, Japan, 3.Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 4.Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan)

[OS2-7B-6] A clinicopathological analysis of CD56-positive cutaneous T cell lymphoma

Tetsuro Ochi¹, Noriko Fukuhara¹, Sayaka Sano¹, Kentaro Nasu², Masahiro Kobayashi³, Satoshi Ichikawa¹, Yoko Okitsu⁴, Yasushi Onishi¹, Minami Fujiwara⁵, Taku Fujimura⁶, Ryo Ichinohasama⁷, Hideo Harigae¹ (1.Department of hematology and rheumatology, Tohoku University hospital, Sendai, Japan, 2.Department of Hematology, Osaki citizen Hospital, Osaki, Japan, 3.Department of hematology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, 4.Department of Transfusion, Tohoku Medical and Pharmaceutical University, Sendai, Japan, 5.Department of blood transfusion, Tohoku University hospital, Sendai, Japan, 6.Department of dermatology, Tohoku University hospital, Sendai, Japan, 7.Department of hematopathology,Tohoku University hospital, Sendai, Japan)